Recent high-quality clinical trial evidence has demonstrated that medications commonly prescribed for migraine prevention in pediatric patients were not superior to placebo for reducing headache symptoms.
Current oral contraceptive products contain lower doses of estrogen than those used in the past, prompting reconsideration of risks and benefits.
Patients with migraine may exhibit higher prevalence of restless leg syndrome, fibromyalgia, and depressive symptoms compared with individuals not experiencing migraines.
The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).
Migraine is highly prevalent in children and adolescents, affecting almost 10% of children between 5 and 15 years old and 30% of adolescents between 15 and 19 years old.
Oral medication, botulinum toxin type A injections, and endoscopic decompression surgery were all compared in the treatment of patients with frontal secondary headaches due to STN and SON configuration.
Investigators examined presenting features of migraine vs arterial ischemic stroke in children presenting to the emergency department.
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Migraines are linked to cardiovascular events, including myocardial infarction, VTE, and stroke.
Researchers examined a possible link between vitamin D, riboflavin, coenzyme Q10, and chronic migraines.
Women who experience migraines had a 50% greater risk for developing major CVD.
For patients with basilar or hemiplegic migraines, two common migraine medications do not increase the risk of stroke and cardiovascular events.
In a study of 4,446 Americans, more than 5% of people with asthma developed chronic migraine, compared to 2.5% of those without.
Headache is one of the most common complaints in outpatient practice. There are 10 things that clinicians need to know to help treat their patients with headache.
Taking a thorough headache history is key for timely migraine diagnosis.
Researchers found no association between patients with clinician-diagnosed migraines and invasive breast cancer.
A man, aged 56, presented with complaints about episodes of vertigo and disabling headaches.
Adolescents ages 12 to 17 can now take the drug, FDA says.
First transcutaneous electrical nerve stimulation device specifically authorized for use prior to onset of pain.
Receiving positive information from a healthcare provider improved migraine outcomes regardless of therapy.
Strongest relationships seen among those younger than 50 years, white and female.
Migraines have been linked to structural brain changes, particularly in the presence of aura.
Children with migraines are more likely to perform poorly in school than those without, with headache severity and duration influencing performance.
If your patient complains of ongoing headaches, especially upon waking from sleep, consider obstructive sleep apnea as a possible cause.
Seizure drugs and beta-blockers can reduce the frequency and severity of migraines.
What treatment would you recommend for aborting a migraine in a patient with known coronary artery disease?
How concerned should clinicians be about serotonin syndrome when prescribing a triptan with a selective serotonin reuptake inhibitor (SSRI)?
A hypertensive patient with migraines experienced undesirable side effects (irritability and weight gain) while taking the nonselective beta-blockers nadolol (Corgard) and propranolol (Inderal).
Risk for death, recurrent myocardial infarction high even with short courses of NSAIDs in patients with established cardiovascular disease and prior MI.
How should a clinician treat a patient with recurring migraines, that also has a history of drug seeking behavior?